A Phase II Study Of Oral LBH589 In Adult Patients With Multiple Myeloma Who Have Received At Least Two Prior Lines Of Therapy And Whose Disease Is Refractory To The Most Recent Line Of Therapy.

Trial Profile

A Phase II Study Of Oral LBH589 In Adult Patients With Multiple Myeloma Who Have Received At Least Two Prior Lines Of Therapy And Whose Disease Is Refractory To The Most Recent Line Of Therapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 May 2013

At a glance

  • Drugs Panobinostat (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms ALPHA-MM
  • Most Recent Events

    • 24 Apr 2012 Company (Novartis Pharmaceuticals Corporation) added as trial sponsor as reported by ClinicalTrials.gov.
    • 16 Mar 2010 Planned end date (1 May 2008) added as reported by ClinicalTrials.gov.
    • 16 Mar 2010 Actual patient number (38) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top